论文部分内容阅读
目的：探讨氨磺必利与奥氮平治疗女性精神分裂症的临床疗效和安全性。方法将50例女性精神分裂症患者随机分为两组，研究组口服氨磺必利治疗，对照组口服奥氮平治疗，观察6周。于治疗前后采用阳性与阴性症状量表评定临床疗效，副反应量表评定不良反应。结果治疗2周末起两组阳性与阴性症状量表总分及各因子分均较治疗前呈持续性下降（ P＜0.05或0.01），治疗6周末研究组显效率59.1％、有效率81.8％，对照组分别为65.2％、86.9％，两组比较差异无显著性（P＞0．05）。两组总体不良反应发生率比较差异无显著性（P＞0．05），但不良反应表现形式有所不同。结论氨磺必利治疗女性精神分裂症疗效显著且与奥氮平相当，安全性高，依从性好。“,”Objective To explore the clinical efficacy and safety of amisulpride and olanzapine in the treatment of female schizophrenia .Methods Fifty female schizophrenics were randomly assigned to two groups taking orally amisulpride or olanzapine for 6 weeks .Efficacies were assessed with the Positive and Negative Syndrome Scale (PANSS) before and after treatment and adverse reactions with the Treatment Emergent Symptom Scales (TESS) .Results Since the end of the 2nd week the PANSS total and each fac‐tor scores of both groups lowered continuously compared with pretreatment (P0.05) .There were no significant group differences in the incidence of total adverse reactions (P>0.05) ,but manifestations of adverse reactions were somewhat different .Conclusion Amisulpride has an evident effect equivalent to olanzapine ,higher safety and better compliance in female schizophrenia .